UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 281

Sortiert nach

BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations

The American journal of surgical pathology, 2015-07, Vol.39 (7), p.977-982

2015

Volltextzugriff (PDF)

Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens

The American journal of surgical pathology, 2016-01, Vol.40 (1), p.120-126

2016

Volltextzugriff (PDF)

Immunohistochemistry as a Practical Tool in Molecular Pathology

Archives of pathology & laboratory medicine (1976), 2016-08, Vol.140 (8), p.766-769

Sheffield, Brandon S

2016

Volltextzugriff (PDF)

Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality

JNCI : Journal of the National Cancer Institute, 2016-06, Vol.108 (6), p.djv428-djv428

2016

Volltextzugriff (PDF)

Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice

PloS one, 2018-04, Vol.13 (4), p.e0196434-e0196434

2018

Volltextzugriff (PDF)

Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care

Current oncology (Toronto), 2022-02, Vol.29 (3), p.1326-1334

2022

Volltextzugriff (PDF)

Loss of BRCA1-associated Protein 1 ( BAP1 ) Expression Is Rare in Non-Small Cell Lung Cancer

Human pathology, 2017-02, Vol.60, p.82-85

2017

Volltextzugriff (PDF)

Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices

Current oncology (Toronto), 2023-02, Vol.30 (2), p.2348-2365

2023

Volltextzugriff (PDF)

Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma

BMC cancer, 2017-09, Vol.17 (1), p.618-618, Article 618

2017

Volltextzugriff (PDF)

Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma

Modern pathology, 2015-10, Vol.28 (10), p.1383-1389

2015

Volltextzugriff (PDF)

Point of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center

Cancers, 2024-07, Vol.16 (14), p.2505

2024

Volltextzugriff (PDF)

Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline

Therapeutic Advances in Medical Oncology, 2022, Vol.14, p.175883592211117-17588359221111705

2022

Volltextzugriff (PDF)

Immunohistochemistry for NF2, LATS1/2, and YAP/TAZ Fails to Separate Benign From Malignant Mesothelial Proliferations

Archives of pathology & laboratory medicine (1976), 2016-05, Vol.140 (5), p.391-391

2016

Volltextzugriff (PDF)

Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing

PloS one, 2015-03, Vol.10 (3), p.e0119689-e0119689

2015

Volltextzugriff (PDF)

Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non–small Cell Lung Cancer

The journal of histochemistry and cytochemistry, 2016-10, Vol.64 (10), p.587-600

2016

Volltextzugriff (PDF)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC

Current oncology (Toronto), 2023-07, Vol.30 (7), p.6473-6496

2023

Volltextzugriff (PDF)

Consensus Recommendations to Optimize the Detection and Reporting of NTRK Gene Fusions by RNA-Based Next-Generation Sequencing

Current oncology (Toronto), 2023-03, Vol.30 (4), p.3989-3997

2023

Volltextzugriff (PDF)

New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?

Archives of pathology & laboratory medicine (1976), 2016-04, Vol.140 (4), p.318-321

2016

Volltextzugriff (PDF)

HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation

Archives of pathology & laboratory medicine (1976), 2014-11, Vol.138 (11), p.1495-1502

2014

Volltextzugriff (PDF)

Canadian Consensus Recommendations on the Management of MET -Altered NSCLC

Current oncology (Toronto), 2021-11, Vol.28 (6), p.4552-4576

2021

Volltextzugriff (PDF)

Novel Approach to Proficiency Testing Highlights Key Practice Variations in Cancer Biomarker Delivery

Journal of Molecular Pathology, 2024-01, Vol.5 (1), p.1-10

2024

Volltextzugriff (PDF)

Report from the Ready for the Next Round Thought-Leadership Roundtables on Building Resilience in Cancer Care and Control in Canada-Colorectal Cancer Canada; 2021

Current oncology (Toronto), 2022-03, Vol.29 (3), p.1723-1743

2022

Volltextzugriff (PDF)

Integrative genomic analysis of ghost cell odontogenic carcinoma

Oral oncology, 2015-09, Vol.51 (9), p.e71-e75

2015

Volltextzugriff (PDF)

Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary

The oncologist (Dayton, Ohio), 2023-06, Vol.28 (6), p.474-478

2023

Volltextzugriff (PDF)

The impact of whole genome and transcriptome analysis (WGTA) on predictive biomarker discovery and diagnostic accuracy of advanced malignancies

The journal of pathology. Clinical research, 2022-07, Vol.8 (4), p.395-407

2022

Volltextzugriff (PDF)

1 – 25 von 281

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(274)

Publikationsform

Sprache

Englisch
(281)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations

Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens

Immunohistochemistry as a Practical Tool in Molecular Pathology

Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality

Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice

Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care

Loss of BRCA1-associated Protein 1 ( BAP1 ) Expression Is Rare in Non-Small Cell Lung Cancer

Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices

Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma

Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma

Point of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center

Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline

Immunohistochemistry for NF2, LATS1/2, and YAP/TAZ Fails to Separate Benign From Malignant Mesothelial Proliferations

Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing

Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non–small Cell Lung Cancer

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC

Consensus Recommendations to Optimize the Detection and Reporting of NTRK Gene Fusions by RNA-Based Next-Generation Sequencing

New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?

HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation

Canadian Consensus Recommendations on the Management of MET -Altered NSCLC

Novel Approach to Proficiency Testing Highlights Key Practice Variations in Cancer Biomarker Delivery

Report from the Ready for the Next Round Thought-Leadership Roundtables on Building Resilience in Cancer Care and Control in Canada-Colorectal Cancer Canada; 2021

Integrative genomic analysis of ghost cell odontogenic carcinoma

Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary

The impact of whole genome and transcriptome analysis (WGTA) on predictive biomarker discovery and diagnostic accuracy of advanced malignancies

Suchergebnisse filtern